376 related articles for article (PubMed ID: 34446728)
21. Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.
Chhibber A; Huang L; Zhang H; Xu J; Cristescu R; Liu X; Mehrotra DV; Shen J; Shaw PM; Hellmann MD; Snyder A
Immunity; 2022 Jan; 55(1):56-64.e4. PubMed ID: 34986342
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943
[TBL] [Abstract][Full Text] [Related]
23. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
Clouthier DL; Lien SC; Yang SYC; Nguyen LT; Manem VSK; Gray D; Ryczko M; Razak ARA; Lewin J; Lheureux S; Colombo I; Bedard PL; Cescon D; Spreafico A; Butler MO; Hansen AR; Jang RW; Ghai S; Weinreb I; Sotov V; Gadalla R; Noamani B; Guo M; Elston S; Giesler A; Hakgor S; Jiang H; McGaha T; Brooks DG; Haibe-Kains B; Pugh TJ; Ohashi PS; Siu LL
J Immunother Cancer; 2019 Mar; 7(1):72. PubMed ID: 30867072
[TBL] [Abstract][Full Text] [Related]
24. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
25. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
[TBL] [Abstract][Full Text] [Related]
26. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y
Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
29. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
30. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Zhang Q; Luo J; Wu S; Si H; Gao C; Xu W; Abdullah SE; Higgs BW; Dennis PA; van der Heijden MS; Segal NH; Chaft JE; Hembrough T; Barrett JC; Hellmann MD
Cancer Discov; 2020 Dec; 10(12):1842-1853. PubMed ID: 32816849
[TBL] [Abstract][Full Text] [Related]
32. Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis.
Li S; Noor ZS; Zeng W; Stackpole ML; Ni X; Zhou Y; Yuan Z; Wong WH; Agopian VG; Dubinett SM; Alber F; Li W; Garon EB; Zhou XJ
Nat Commun; 2021 Jul; 12(1):4172. PubMed ID: 34234141
[TBL] [Abstract][Full Text] [Related]
33. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.
Richard C; Fumet JD; Chevrier S; Derangère V; Ledys F; Lagrange A; Favier L; Coudert B; Arnould L; Truntzer C; Boidot R; Ghiringhelli F
Clin Cancer Res; 2019 Feb; 25(3):957-966. PubMed ID: 30154227
[TBL] [Abstract][Full Text] [Related]
34.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
35. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
36. Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA.
Zhou C; Weng J; Liu S; Zhou Q; Hu Z; Yin Y; Lv P; Sun J; Li H; Yi Y; Shen Y; Ye Q; Shi Y; Dong Q; Liu C; Zhu X; Ren N
Hepatol Int; 2023 Dec; 17(6):1461-1476. PubMed ID: 37217808
[TBL] [Abstract][Full Text] [Related]
37. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
38. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
39. Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
Ayers M; Nebozhyn M; Cristescu R; McClanahan TK; Perini R; Rubin E; Cheng JD; Kaufman DR; Loboda A
Clin Cancer Res; 2019 Mar; 25(5):1564-1573. PubMed ID: 30442684
[TBL] [Abstract][Full Text] [Related]
40. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
George S; Miao D; Demetri GD; Adeegbe D; Rodig SJ; Shukla S; Lipschitz M; Amin-Mansour A; Raut CP; Carter SL; Hammerman P; Freeman GJ; Wu CJ; Ott PA; Wong KK; Van Allen EM
Immunity; 2017 Feb; 46(2):197-204. PubMed ID: 28228279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
